Developing antibodies that work better with changes in pH
Engineering and Characterization of pH dependent Antibodies
['FUNDING_R15'] · NORTHERN ILLINOIS UNIVERSITY · NIH-10974952
This study is exploring how to make antibodies that can adjust their actions based on the acidity in the body, which could lead to better treatments for patients by making these antibodies work more effectively in different conditions.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHERN ILLINOIS UNIVERSITY (nih funded) |
| Locations | 1 site (DE KALB, UNITED STATES) |
| Trial ID | NIH-10974952 on ClinicalTrials.gov |
What this research studies
This research focuses on engineering antibodies that can change their behavior based on pH levels, which could enhance their effectiveness in various medical applications. By introducing specific acidic residues, the researchers aim to create antibodies that can better regulate their interactions with antigens, potentially leading to improved therapies. The project will involve detailed characterization of these antibodies to understand how they function in different pH environments. Patients may benefit from advancements in antibody-based treatments that are more responsive to the body's changing conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who require antibody-based therapies for conditions such as cancer or other diseases where antibody function is critical.
Not a fit: Patients who do not require antibody therapies or those with conditions unrelated to antibody function may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibody therapies that adapt to the body's pH levels, improving treatment outcomes for patients.
How similar studies have performed: While the approach of engineering pH-dependent antibodies is innovative, similar strategies in antibody design have shown promise in other research, suggesting potential for success.
Where this research is happening
DE KALB, UNITED STATES
- NORTHERN ILLINOIS UNIVERSITY — DE KALB, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HORN, JAMES R. — NORTHERN ILLINOIS UNIVERSITY
- Study coordinator: HORN, JAMES R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.